Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

November 11, 2024

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

News Conference News SCAI 2023

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

May 24, 2023

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

Adjunctive Radial Artery Grafts No Better Than SVGs in Multivessel CABG

News Conference News EACTS 2022

Adjunctive Radial Artery Grafts No Better Than SVGs in Multivessel CABG

Michael O'Riordan

October 12, 2022

CCTA in Patients With Prior CABG Cuts Complications of Invasive Angio: BYPASS-CTCA

News Conference News TCT 2022

CCTA in Patients With Prior CABG Cuts Complications of Invasive Angio: BYPASS-CTCA

Yael L. Maxwell

September 21, 2022

TiCAB: Ticagrelor No Help for Preventing Graft Failure Post-CABG

News Conference News AHA 2018

TiCAB: Ticagrelor No Help for Preventing Graft Failure Post-CABG

November 13, 2018

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

EVAR Outcomes Equivalent Between Men and Women, Registries Show

News Conference News VIVA 2017

EVAR Outcomes Equivalent Between Men and Women, Registries Show

September 14, 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News AHA 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

November 28, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.